Japan· JP-6399427A2023
ラブリズマブ（遺伝子組換え）
A medicinal product containing ラブリズマブ（遺伝子組換え）, registered in Japan by アレクシオンファーマ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ラブリズマブ（遺伝子組換え）
- Manufacturer
- アレクシオンファーマ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
ラブリズマブ（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandUltomirisAlexion Europe SAS
- SwedenUltomiris 1100 mg/11 ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- BelgiumUltomiris 1100 mg/11 mlAlexion Europe
- CzechiaULTOMIRISAlexion Europe SAS, Levallois-Perret
- United KingdomUltomiris 1,100mg/11ml concentrate for solution for infusion vialsAlexion Pharma UK Ltd
- United StatesUltomirisAlexion Pharmaceuticals Inc.
- CanadaULTOMIRISALEXION PHARMA GMBH
- SwitzerlandUltomiris 1100 mg/11 ml, Konzentrat zur Herstellung einer InfusionslösungAlexion Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
- Norway · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2bc5b215-7525-4f4c-8106-2ea9a1c56a9a GET /v1/drugs/2bc5b215-7525-4f4c-8106-2ea9a1c56a9a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "３００ｍｇ３ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6399427A2023",
"category": "注射薬",
"price_yen": 659985,
"generic_name": "ラブリズマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "6399",
"transitional_expiry": null
}See everything about ラブリズマブ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.